Menu Search
Equities

Medesis Pharma SA

76D:MUN

Medesis Pharma SA

Actions
  • Price (EUR)0.40
  • Today's Change0.00 / 0.00%
  • Shares traded42.00
  • 1 Year change-60.20%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medesis Pharma SA is a France-based clinical development stage biopharmaceutical Company. The Company is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-3.96m
  • Incorporated2003
  • Employees10.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.